Cooley LLP‘s broad ECM expertise spans IPOs, follow-on offerings, and ADS offerings, with the group standing out particularly when it comes to IPOs by European issuers. With a strong presence in the key capital markets hubs of New York, Chicago, Boston, and California, the group is well placed to advise clients in the tech, e-commerce, and healthcare/life sciences sectors in particular. Charlie Kim in San Diego is especially strong when it comes to biotech and life sciences IPOs. He chairs the group alongside David Peinsipp in San Francisco, whose varied practice spans IPOs, follow-on offerings, and 144A offerings, among other matters. Div Gupta in New York boasts a blue-chip client roster that includes major healthcare and life sciences companies as well as leading investment banks; he regularly handles IPOs, follow-on offerings, and ADS offerings. Palo Alto’s Eric Jensen is noted for advising high-growth tech, consumer, and life sciences companies as well as investment banks. Boston-based Marc Recht has a strong track record working for European-based issuers in the life sciences space.
L’éditorial du Legal 500
- Profil
Témoignages
Collectés indépendamment par l'équipe de recherche du Legal 500.
- 'I have been extremely impressed with the entire Cooley team. Unlike most other firms, the attorneys we work with are full life cycle, meaning they are experts in both private company and public company transactions. So, it is the same team who can represent us in any transaction, and who can seemlessly integrate other partners into workstreams without us losing a primary point of contact.'
Clients clés
- Life360
- Silence Therapeutics
- Ambrx Biopharma
- Autolus Therapeutics
- Bicycle Therapeutics
- Evercore Group
- Exscientia
- Valneva
- UroGen Pharma
- Goldman Sachs & Co.
Points forts
- Advised Life360 on its $178.5 million IPO of 6,612,500 shares of common stock at a public offering price of $27 per share.
- Advised Enlitic on its AU$21 million IPO of 25,366,165 CHESS Depositary Interests (CDIs) over shares of common stock at an issue price of AU$0.83 per CDI.
- Advised Structure Therapeutics on its upsized approximately $547.4 million S-1 follow-on offering of 10,427,017 ADSs, each representing three ordinary shares, at a public offering price of $52.50 per ADS, which included the exercise in full of the underwriters’ option to purchase an additional 1,360,045 ADSs in the offering.
Avocats
Responsable de la pratique
Charlie Kim; David Peinsipp
Autres avocats clés
Div Gupta; Eric Jensen; Marc Recht